◆ 会议时间：2022年11月4-8日
◆ 会议地点：美国 华盛顿

◆ 会议简介：

2022年第73届美国肝病研究协会(AASLD)年会将于2022年11月4-8日在美国华盛顿举行。美国肝病年会(The Liver Meeting)是目前世界上最大、最具权威的肝脏病学会议，每年都有来自世界各地的9000余名肝病学家和从事肝病研究的专业人士前来参会，一起分享探讨肝病学领域的突破性研究成果、新的治疗指南以及最新的治疗进展。

美国肝病研究学会（AASLD）成立于1950年，是全球领先的由致力于预防和治疗肝脏疾病的科学家和相关专业人士组成的国际性组织，现在世界各地拥有超过5200名会员，包括肝脏病学家、外科医生、科学家和其他卫生保健专业人员等。AASLD通过教育会议、培训计划、专业出版物宣以及与政府机构和姐妹社团的合作，推进肝病学的科学和实践，改善患者的护理质量，为数百万肝病患者提供科学的治疗方案。AASLD的愿景是预防和治愈肝脏疾病（未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网lingyuint.com）。

The Liver Meeting® 2022 - The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Date: November 4-8, 2022
Venue: Walter E. Washington Convention Center, Washington, DC, USA

WHO ATTENDS THE LIVER MEETING

The Liver Meeting® brings together attendees from around the world to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field. Our attendees include those focused on:

• Adult and pediatric hepatology
• Clinical, basic and translational researchers
• Specialists who diagnose and treat liver disease, including gastroenterologists, surgeons, pathologists, anesthesiologists and radiologists
• Primary care physicians
• NPs, PAs, RNs, pharmacists and other allied health professionals
• Trainees and students in all disciplines listed above

摘要征集：

• Regular Abstract Submission Opens: April 1, 2022
• Regular Abstract Submission Closes: June 1, 2022
• Abstract Notifications Sent: August 1, 2022
• Late-breaking Abstract Submission Opens: September 8, 2022
• Late-breaking Abstract Submission Closes: September 15, 2022

点此提交摘要>>>Submit Abstract>>>

摘要提交指南>>>Abstract Submitter Guide>>>

Oral Abstracts and Poster Presenters

General Information

• Abstracts must be received by 11:59 pm ET, Wednesday, June 1, 2022 to be considered for review.
• Abstracts received after the deadline will not be accepted and incomplete abstracts will be considered ineligible for inclusion.
• Abstracts must be submitted online through the abstract submission site. No faxed copies, discs, thumb drives or email submissions will be accepted.
• An abstract may only be submitted to The Liver Meeting® once. Duplicate abstracts (reporting the same data) that are submitted under a different author will be administratively withdrawn.
• To submit an abstract, there is a nonrefundable fee of $70. Authors can pay by VISA®, MasterCard®, American Express® or DISCOVER®; your credit card will be processed by AASLD. Please be sure to list the current expiration date of your credit card.
• Abstracts will not be considered for publication and/or presentation unless payment is provided before the submission deadline. No checks or purchase orders will be accepted.
• Case reports, or novel clinical observations can provide new insight into clinical phenotypes or pathogenesis of disease. Case reports are not frequently submitted to The Liver Meeting® but authors who so choose may submit one using the same guidelines outlined below for standard abstract submission. Case reports will be scored and ranked by the same review team that scores abstract submissions for the category and descriptor selected by the submitting author.

Title

• The title should be brief, but long enough to clearly identify the nature of the study. Omit author degrees, titles and institutional appointments.
• Do not include authors in the title. Abstracts containing authors in the title will be administratively withdrawn.
• Authors must be entered in the abstract submission process.

Authors

• Indicate the name and location of the institution where the work was done.
• If an author's name appears on more than one abstract, it must be identical on each abstract.
• Be sure to include the correct email address for each author upon submission, as this is the only way AASLD will contact authors. Authors will not be able to make changes to any author information past the submission deadline.
• Authors may submit more than one abstract in which they are indicated as the presenting author, but they may only present one oral presentation. If more than one abstract is selected for oral presentation, an alternate presenter must be assigned, preferably a co-author. This does not apply to paper posters presented in the Exhibit Hall.
• Presenting authors and co-authors will receive all notifications and communications related to the accepted abstract(s). Please note AASLD is not responsible for communication between authors. Authors should remain in communication about the status of their abstract(s), disclosures, presentation details and all other information regarding their abstract(s).
• There is no limit to the number of authors included per abstract.

Author Disclosure

By submitting an abstract to be considered for presentation at the Annual Meeting, you agree to comply with AASLD’s Disclosure Policy and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Additionally:

• Disclosures will be collected from presenting authors at the time of abstract submission.
• Presenting authors must provide financial disclosures to be considered for inclusion at The Liver Meeting®. If disclosures are not received by the deadline provided in the acceptance notice, the work will be withdrawn from the meeting.
• Author disclosure of potential conflicts with a commercial interest, for all authors, must be disclosed. (A commercial interest is defined as any entity developing, producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.) Any potential conflict will be identified and managed according to ACCME guidelines.

Abstract Body

The body of the abstract must include the following sections:

• Background: summarize the purpose, scope and objectives of the study or research.
• Methods: describe the methods used to measure your study/research.
• Results: A summary of the results obtained.
• Conclusion: A statement of conclusions reached in your study or research. Do not simply state "The results will be discussed." (Abstracts will not be considered for presentation if this statement is made.)

Abstract Size

• The abstract size is limited to 2,500 characters in the abstract body (including spaces), with an option of up to one image for inclusion in addition to the 2500 characters.
• Please do not include more than one table or graphic, limited in size to 2" height by 3" width.

Abbreviations

• Abbreviations should conform to the recommendations made by the IUB Committee of Editors on Biochemical Journals.
• Use abbreviations in parentheses after the full word the first time it appears. Use no more than three nonstandard abbreviations.

Abstract Category and Subcategory

• Before you submit, review the list of Abstract Categories and Subcategories.
• During the submission process (Step 2) you will be prompted to select a category that best characterizes your research, along with a matching subcategory. These categories will be used to classify abstracts for publication and review.
• The Scientific Program Committee reserve the right to re-categorize any abstract as deemed appropriate.

Content

• Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices should not be used in the title or body of the abstract. Use of generic names will contribute to impartiality.
• The Scientific Program Committee reserves the right to change the abstract if they feel that the use of a trade name may be mistaken for commercial propaganda and may replace proprietary names with generic names. In addition, logos representing a commercial interest will be removed prior to presentation.
• If the session material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company.

Drug Names

• Drug products mentioned in the abstract should be identified by their nonproprietary (i.e. generic) name only.
• Do not capitalize nonproprietary names.

Late-breaking Abstract Submission Criteria

• Late-breaking Abstract Submission Opens: September 8, 2022
• Late-breaking Abstract Submission Closes: September 15, 2022

Original late-breaking scientific research conducted and submitted after the original abstract deadline will be reviewed for presentation at The Liver Meeting®. Abstracts are considered "late-breaking" if the works meet the following criteria:

• The research must be new and of sufficient scientific importance to merit special consideration after the standard abstract deadline. Abstracts should describe either large clinical studies or high-impact translational research that could not be completed prior to the original deadline.
• Clinical studies must be prospective in design. Authors must justify late consideration by documenting the closure date of the study, which must be March 9 or later (12 weeks before the closure of the abstract submitter). Phase 1 trials will be considered for presentation, but only in poster format.
• Phase 2/3 trials will be considered for presentation in either oral or poster format. Retrospective studies are not eligible for consideration in the late-breaking category.
• Laboratory-based studies are not typically considered appropriate as late submissions and must be strongly justified. Authors must specify why experiments could not be completed before the standard abstract deadline.
• Late-breaking abstracts cannot be a revision of an abstract submitted prior to the submission deadline.
• Late-breaking abstracts must not have been presented, accepted for presentation, or published in any other scientific venue.
• All late-breaking abstracts must be accompanied by a brief statement from the authors documenting the reason for eligibility in the clinical or laboratory-based category.

What To Expect This Year

Programming at The Liver Meeting will primarily be delivered live in person, with some sessions live-streamed to the TLMdX platform. Sessions will be captured and made available on the platform within 72 hours, or sooner, of their in-person delivery. Some educational content will also be available on-demand at the start of the meeting. Attendees can anticipate:

• The latest research on disease states like NAFLD, NASH, Hepatitis and much more.
• Educational sessions from leading hepatologists and public health experts from around the globe on the effects of the COVID-19 virus from both clinical and public health perspectives.
• The specialty’s leading minds in our popular Meet-the-Expert sessions.
• Ample opportunities to connect with your peers.
• The patient perspective provided by special Patient Advocacy Group programming.
• All educational programming will be available on the platform through February 2023

AASLD The Liver Meeting (TLM) 注册费：

In-Person Experience(TLM) or Digital Experience(TLMdx)

Regular Rates(ends 11/07)
Member $655
Non-Member $1750
Member Associate or Trainee $445
Non-Member Associate or Trainee $865
Member Student $150
Non-Member Student $505
Patient Advocate $50
Patient or Caregiver $50

View the full rate chart here.

企业参展/卫星会申请：
exhibits@aasld.org
卫星会申请和提案必须在2022年6月24日之前提交。

AASLD invites commercial supporters of The Liver Meeting® 2022 to organize a limited number of independent educational symposia to be presented for registered attendees. These symposia will take place at designated times following scheduled educational events of The Liver Meeting® and are designed to meet the continuing medical education needs of the hepatology community. Completed applications and proposals must be submitted to exhibits@aasld.org by Friday, June 24, 2022.

◆ 参会对象：成人和儿童肝病专家；临床、基础和转化研究人员；诊断和治疗肝脏疾病的专家/医师，包括胃肠病学家、外科医生、临床病理学家、麻醉师和放射科医生；初级保健医生；执业护士、注册护士、医师助理、药剂师及其它肝病学和上述学科的相关医护人员、学员/学生等等。